Regional Gene Therapy Liaison - Rare Disease Focus

Krystal Biotech; Oklahoma City (OK); Hybrid; USD 90,000 - 130,000; Full time

Job summary

Krystal Biotech, Inc. is seeking a Regional Gene Therapy Liaison to lead field-based promotion of Vyjuvek to pediatric dermatologists and other DEB stakeholders across TX, OK, MO, AR, KS with top-priority regional goals.

The role offers significant territory ownership, frequent travel (≥75%), and an entry point into ultra-rare gene therapy, with six-month at-will term and potential for extension based on performance and business needs.

Qualifications

• Bachelor's degree required.
• Minimum 5+ years of sales experience with at least 1+ year in pharmaceutical sales.
• Experience in specialty, hospital, or complex selling environments is a plus.
• Exposure to multi-stakeholder selling models and reimbursement environments is beneficial.
• Ability to travel up to 75%+ and reside near the territory.

Responsibilities

• Promote Vyjuvek to pediatric dermatologists and other DEB stakeholders within the region.
• Develop territory strategies for market development, brand awareness, and patient identification.
• Educate HCPs on Vyjuvek's indication, safety, and efficacy through in-person and virtual meetings.
• Manage time, travel, and resources to optimize access to healthcare professionals.
• Build consultative sales relationships and maintain professional communication with customers and prospects.
• Collaborate with cross-functional teams to support access and coordination at care sites.

Skills

Sales experience

Pharma sales

Territory management

Communication skills

Travel readiness

Cross-functional collaboration

Education

Bachelor's degree

Tools

CRM software

Job description

Krystal Biotech, Inc. is seeking a Regional Gene Therapy Liaison to lead field-based promotion of Vyjuvek to pediatric dermatologists and other DEB stakeholders across TX, OK, MO, AR, KS with top-priority regional goals.

The role offers significant territory ownership, frequent travel (≥75%), and an entry point into ultra-rare gene therapy, with six-month at-will term and potential for extension based on performance and business needs.